15:50:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Paxman är verksamma inom skalpkylning, som används för patienter som behandlas för cytostatika. Bolagets produkt Paxman Scalp Cooler används för att minimera håravfallet hos patienten under behandlingens gång. Scalp Coolern är en fristående, mobil och eldriven kylenhet som kyler ner patientens hårbotten via en kylmössa. Bolaget grundades 1996 och har idag sitt huvudkontor i Karlshamn.

Kalender

2023-05-24 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning PAX 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning PAX 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-26 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning PAX 0.00 SEK
2020-05-27 Kvartalsrapport 2020-Q1
2020-05-27 Årsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning PAX 0.00 SEK
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-23 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning PAX 0.00 SEK
2018-05-24 Årsstämma 2018
2018-05-24 Kvartalsrapport 2018-Q1

Prenumeration

2022-06-22 08:00:00

Today, Paxman publishes the June issue of its newsletter aimed at shareholders, investors and other interested parties.

This month’s issue highlights that the American Medical Association (AMA) resolved to advocate for and seek through legislation and/or regulation, universal insurance coverage for scalp cooling therapy at the annual meeting for its principal policy-making body House of Delegates (HOD). At the meeting, AMA also resolved to work with consumer and advocacy groups to challenge insurers on medical necessity denials for scalp cooling therapy and encourage appeals of such decisions.

The newsletter also includes information on that Paxman celebrated five successful years in the US at the recent ASCO annual meeting, this month’s orders and installations in the US, the UK and rest of the world including 10 systems to Japan, that Paxman won the National Medilink UK Award for Outstanding Achievement, and the fourth episode of the Changing the Face of Cancer podcast where the chemotherapy side effect CIPN is discussed.

To read the newsletter and subscribe for upcoming issues, follow this link:

https://bit.ly/paxjun22en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.